- Home
- SANA vs FDMT Comparison
SANA vs FDMT Comparison
Compare SANA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANA | FDMT |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.1M | 695.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SANA | FDMT |
|---|---|---|
| Price | $2.90 | $13.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $8.43 | ★ $27.82 |
| AVG Volume (30 Days) | ★ 3.4M | 773.8K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.24 | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $2.61 | $6.96 |
| 52 Week High | $6.55 | $16.93 |
Technical Indicators
Market Signals| Indicator | SANA | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 50.33 |
| Support Level | $2.64 | $13.39 |
| Resistance Level | $3.41 | $15.29 |
| Average True Range (ATR) | 0.17 | 0.88 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 11.77 | 37.21 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).